Pneumotox » Drug » Azathioprine

Azathioprine

3

Last update : 13/08/2012

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

2

I.b Pneumonitis (ILD)

2

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

-

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

1

I.g Pulmonary fibrosis

1

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

1

I.m ILD with a granulomatous component

1

I.q Pulmonary nodulosis

1

I.ah Acute restrictive lung dysfunction

1

II.b ARDS - Acute lung injury

1

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

1

VIII.a Angioedema (may cause UAO, asphyxia and death)

1

X.g Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

1

X.o Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

1

XII.h Eosinophilic myocarditis

1

XIII.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

1

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

1

XV.e Path: ILD with a granulomatous component (see also Im)

1

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

1

XV.j Path: Pulmonary fibrosis (UIP-pattern)

1

XV.bq Path: Lymphoproliferative disease, endothoracic

1

XVII.e Pneumocystis jiroveci pneumonia

1

XVII.h Nontuberculous pulmonary mycobacterial infection/superinfection

1

XIX.a BAL: An excess proportion of lymphocytes

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist